Manufacturing and Royalty Revenues Revenue earned during the period from the sale of goods manufactured and royalty revenues received related to the sale, leasing or otherwise lending to a third party the entity's rights or title to under certain license arrangements. Manufacturing and royalty revenues COLLABORATIVE ARRANGEMENTS Schedule of investments Investment [Table Text Block] Document and Entity Information Increase (Decrease) in Inventory, Prepaid Expenses and Other Assets Inventory, prepaid expenses and other assets Increase (Decrease) In Inventory, prepaid expenses and other assets. Represents the minimum number of commercial drug products in portfolio. Minimum Number of Commercial Drug Products in Portfolio Minimum number of commercial drug products in Company's diversified portfolio Threshold for Disclosure Percentage Threshold percentage for disclosure of revenue and receivables The minimum percentage of revenues or receivables from a single customer that is used as a threshold for disclosure of a concentration of risk. Defined Contribution Plan, Employee Contribution Limit as Percentage of Compensation Employee contribution limit as a percentage of their eligible compensation The limit of annual employee contributions to the plan, as a percentage of compensation. Receipt of Company Stock for Purchase of Stock Options or to Satisfy Minimum Tax Withholding Obligations Related to Stock Based Awards, Value Receipt of Alkermes' stock for the purchase of stock options or to satisfy minimum tax withholding obligations related to stock based awards This element represents Receipt of Alkermes' stock for the purchase of stock options or to satisfy minimum tax withholding obligations related to stock based awards. Receipt of Company Stock for the Purchase of Stock Options or to Satisfy Minimum Tax Withholding Obligations Related to Stock Based Awards, Shares Receipt of Alkermes' stock for the purchase of stock options or to satisfy minimum tax withholding obligations related to stock based awards (in shares) This element represents Receipt of Alkermes' stock for the purchase of stock options or to satisfy minimum tax withholding obligations related to stock based awards. Shares acquired by means of net share settlements, related to the vesting of employee stock options to satisfy withholding tax obligations Principal payments on long-term debt attributable to original issue discount Represents principal payments of long-term debt attributable to original issue discount during the reporting period. Payment of Instrument Principal Attributable to Original Issue Discount Amendment Description Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale, located at third party warehouse and shipping service provider. Inventory Finished Goods Net of Reserves Located at Third Party Warehouse and Shipping Service Provider Finished goods inventory located at third-party warehouse and shipping service provider Amendment Flag Strategic equity investments Represents information pertaining to strategic equity investments in corporations and other legal entities represented by shares of common or preferred stock (which is neither mandatorily redeemable no redeemable at the option of the holder), convertible securities, stock rights, or stock warrants. Strategic investments Strategic Equity Investments [Member] Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Number of Investments Valued as Level 3 Represents the number of investments valued as level 3 of the fair value hierarchy. Number of investments valued as level 3 Prepayment penalty in connection with debt refinancing Prepayment of Penalty on Debt Refinancing The cash outflow from a prepayment of penalty in connection with debt refinancing. Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Number of Investments Transfers from Level 2 to Level 1 Number of investments transferred from level 2 to level 1 Represents the number of investments transferred into level 1 from level 2 of the fair value hierarchy. Number of investments transferred from level 3 to level 2 Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Number of Investments Transfers from Level 3 to Level 2 Represents the number of investments transferred from level 3 to level 2 of the fair value hierarchy. Represents the First Lien Term Loan which is due on September 16, 2017 and is secured by a first priority lien on substantially all of the assets and properties of the company and the guarantors. First Lien Term Loan, due September 16, 2017 First Lien Term Loan, due September 16, 2017 First Lien Term Loan [Member] First Lien Term Loan All Countries [Domain] Second Lien Term Loan [Member] Second Lien Term Loan Represents the Second Lien Term Loan which is due on September 16, 2018 and is secured by a second priority lien on substantially all of the assets and properties of the company and the guarantors. Second Lien Term Loan, due September 16, 2018 Disclosure of the carrying value of finite-lived and indefinite-lived intangible assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in operations of a company. Schedule of Finite-Lived and Indefinite-Lived Intangible Asset by Major Class [Table] Finite-Lived and Indefinite-Lived Intangible Assets [Line Items] Intangible assets Business Acquisition Cost of Acquired Entity [Table Text Block] Schedule of purchase price of the EDT business Disclosure of the total purchase price for the acquisition. Schedule of Current and Noncurrent Deferred Tax Assets Liabilities [Table Text Block] Schedule of current and non-current deferred tax assets (liabilities) Tabular disclosure of current and noncurrent portion of deferred tax assets and liabilities. Proceeds from the sales and maturities of marketable securities, plus the resulting realized gains and losses Tabular disclosure of the proceeds from sales and maturities of marketable securities, plus the resulting realized gains and losses. Proceeds and Realized Gain (Loss) on Marketable Securities [Table Text Block] Long-term investments Represents information pertaining to long-term investments. Long-term Investments [Member] Marketable Securities at Amortized Cost Amortized Cost Represents the cost of debt and equity securities, which are categorized as held-to-maturity, trading securities and available-for-sale, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any. Gross Unrealized Losses, Less than One Year Represents the excess of amortized cost basis over the fair value of securities that have been in a loss position for less than twelve months for those securities that are categorized as held-to-maturity, trading securities and available-for-sale. Marketable Securities Continuous Unrealized Loss Position Less than 12 Months Aggregate Losses Marketable Securities Continuous Unrealized Loss Position 12 Months or Longer Aggregate Losses Gross Unrealized Losses, Greater than One Year Represents the excess of amortized cost basis over the fair value of securities that have been in a loss position for twelve months or longer for those securities that are categorized as held-to-maturity, trading securities and available-for-sale. Current Fiscal Year End Date Award Type [Axis] Realized gains Represents the profit realized on the sale of debt or equity securities categorized as held-to-maturity, trading securities and available-for-sale. Marketable Securities Realized Gain Realized losses Represents the loss realized on the sale of debt or equity securities categorized as held-to-maturity, trading securities and available-for-sale. Marketable Securities Realized Loss Maximum amount per employee, by the terms of the plan, that the employee may contribute to a defined contribution plan. Per employee contribution limit Defined Contribution Plan, Annual Contribution by Per Employee Amount Civitas Therapeutics Inc [Member] Civitas Represents information pertaining to Civitas Therapeutics, Inc. Shares of Series A preferred stock issued Represents the total number of preferred shares issued by the equity method investee. Equity Method Investee Preferred Stock Shares Issued Equity Method Investee Proceeds from Preferred Stock Shares Issued Proceeds from issuance of shares of Series A preferred stock Represents the proceeds from issuance of preferred shares issued by the equity method investee. Percentage of Series A preferred stock received by the entity Represents the percentage of preferred shares, issued by the equity method investee, received by the entity. Equity Method Investment Percentage of Preferred Stock Shares Received Maximum employee contribution limit as a percentage of their total taxable earnings The limit of annual employee contributions to the plan, as a percentage of their total taxable earnings. Defined Contribution Plan, Maximum Employee Contribution Limit as Percentage of Total Taxable Earnings Equity Method Investment Amortization Period of Deferred Gain Period of amortization of deferred gain Represents the period over which the gain on equity method investment will be amortized. Furniture, fixtures and equipment Furniture Fixture and Equipment [Member] Represents furniture, fixture and equipment of the entity. Stock Option and Incentive Plan 2008 [Member] 2008 Plan Represents the 2008 Stock Option and Incentive Plan which provides for issuance of non-qualified and incentive stock options, restricted stock, restricted stock units, cash-based awards and performance shares to employees, officers and directors of, consultants to the company. Document Period End Date Revenues, Net [Member] Aggregate revenues, net, during the period in the normal course of business. Revenues, net Name of the defined contribution plan. Defined Contribution Benefit Plans [Domain] Defined contribution 401 (k) plan. 401 (K) Plan Plan 401 (K) [Member] Defined Contribution Plan Represents the defined contribution plan for employees outside the reporting entity's home country. Foreign Defined Contribution Plans [Member] 2011 Plan Represents the 2011 Stock Option and Incentive Plan which provides for issuance of non-qualified and incentive stock options, restricted stock, restricted stock units, cash-based awards and performance shares to employees, officers and directors of, consultants to the company. Stock Option and Incentive Plan 2011 [Member] Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans under which No Further Awards will be Made Number of share-based compensation plans under which no further awards will be made Represents the number of equity-based compensation plans under which no further awards will be made. Number of share-based compensation plans under which awards are currently made Represents the number of equity-based compensation plans under which awards are currently made. Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans under which Awards are Currently Made Notional value Derivative, Notional Amount Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Options Count Against Number of Shares Available for Grant Ratio Represents the ratio of awards other than stock options counted against the total number of shares available for issuance. Ratio of awards other than stock options counted against the total number of shares available for issuance Share-based Compensation Arrangement by Share-based Payment Award Options Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Entity [Domain] Time Vested Restricted Stock Units [Member] Time-vested RSUs Represents the time-vested restricted stock units awarded by the company to its employees as a form of incentive compensation. Represents performance based restricted stock units as awarded by a company to their employees as a form of incentive compensation. Performance-based Restricted Stock Units [Member] Performance-based RSUs Plan 2006 [Member] 2006 Plan Represents information pertaining to 2006 plan. Arrangements and Non-arrangement Transactions [Domain] Plan 2002 [Member] 2002 Plan Represents information pertaining to 2002 plan. Marketable Securities [Domain] Provides the general categories of investments that may be classified as available-for-sale, held-to-maturity and trading, for which information is required or is determined to be disclosed. Schedule of Acquired Intangible Assets [Table Text Block] Summary of intangible assets acquired Tabular disclosure of the major classes of acquired intangible assets. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company. Elan Drug Technologies [Member] EDT Represents information pertaining to Elan Drug Technologies. Cash Flow Reclassification [Member] Reclassifications to statement of cash flows Represents the activity related to reclassifications to previously reported amounts on the Statement of Cash Flows. Operations and Comprehensive Income (Loss) Reclassification [Member] Reclassifications to statements of operations and comprehensive income (loss) Represents the activity related to the reclassifications to previously reported amounts on the statements of operations and comprehensive income (loss). Business Acquisition, Pro Forma Earnings Per Share Basic and Diluted Basic and diluted (loss) per ordinary share The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of the period. Intangible Assets Acquired as Part of Business Combination [Table] A table containing detailed characteristics of finite-lived and indefinite-lived intangible assets acquired during a business combination. Intangible assets are assets that have no physical form. Acquired finite-lived and indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total. Intangible Assets Acquired as Part of Business Combination [Line Items] Intangible assets acquired Schedule of Defined Contribution Benefit Plans Disclosures [Table] Disclosures about defined contribution plans. Defined Contribution Benefit Plans [Line Items] Employee benefit plans Defined Contribution Benefit Plans, Disclosure Benefit Plans [Axis] Disclosures about defined contribution plan. Vesting Rights Percentage Vesting rights per year (as a percent) Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, shown as a percentage. Debt Instrument, Periodic Payment as Percentage of Principal Amount Term Loan quarterly amortization price as percentage of original principal amount Represents the amount of the required periodic payments applied to principal as percentage of original principal amount. Incremental capacity Represents the amount of incremental capacity available so long as the entity meets certain conditions. Debt Instrument Incremental Capacity Subject to Satisfaction of Certain Conditions Operating Lease Term Term of operating leases Represents the term of the operating lease. Represents the provision for extension of operating lease term. Operating Lease Provision for Extension of Term Provisions for extension of lease term Total future minimum lease payments The total of future contractually required payments on leases, net of related future sublease operating rental income receivable. Operating Leases Future Minimum Payments Due Net of Sublease Purchase commitments Purchase Commitments [Abstract] Deferred Tax Assets and Liabilities Classification [Abstract] Schedule of current and non-current deferred tax assets (liabilities) Tabular disclosure of current and noncurrent portion of deferred tax assets and liabilities. Additional tax benefits from stock option exercises that have not been recognized Deferred Tax Assets, Tax Deferred Expense Compensation and Benefits Exercise of Stock Options Tax benefit from the exercise of stock options The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from exercise of stock options, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Income Taxes [Table] Disclosures pertaining to income taxes. Income Taxes [Line Items] Income taxes Distribution of income (loss) before provision for income taxes Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from exercise of stock options, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. This element includes the additional tax benefits from the exercise of stock options related to the adoption of ASC 718, that have not been recognized in the financial statements. Deferred Tax Assets, Tax Deferred Expense Compensation and Benefits Exercise of Stock Options Including Additional Tax Benefits Total tax benefit from the exercise of stock options including unrecognized benefits The component of income tax expense for the period representing amounts paid or payable as determined by applying the provisions of enacted state and local tax law to the amount of taxable transfer of intellectual property. Current State and Local Tax Expense from Transfer of Intellectual Property Provision on taxable transfer of the BYDEREON intellectual property Income tax expense associated with the increase in the value of certain securities The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to increase in fair value of securities. Deferred Income Tax Benefit Increase in Fair Value of Securities Tax benefit in connection with the Business Combination The component of total income tax expense for the period comprised of an increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to business combination as determined by applying the provisions of the US federally enacted tax law. Deferred Federal Income Tax Benefit in Connection with Business Combination Nano Crystal Technology [Member] NanoCrystal technology Information pertaining to NanoCrystal technology, an intangible asset acquired from third parties. Information pertaining to OCR technology, an intangible asset acquired from third parties. OCR Technology [Member] OCR technology License Agreement [Member] Represents information pertaining to the license agreement included under the collaboration agreement. License agreement Manufacturing and supply agreement Manufacturing and Supply Agreement [Member] Represents information pertaining to the manufacturing and supply agreement included under the collaboration agreement. Development and License Agreement [Member] Represents information pertaining to the development and license agreement included under the collaboration agreement. Development and license agreement Represents Janssen, a collaborative partner of the entity. Janssen [Member] Janssen Acorda [Member] Acorda Represents Acorda, a collaborative partner of the entity. Bristol Myers [Member] Bristol-Myers Represents Bristol-Myers, a collaborative partner of the entity. RISPERDAL CONSTA [Member] RISPERDAL CONSTA Represents information pertaining to RISPERDAL CONSTA, a product of the entity. INVEGASUSTENNA or XEPLION [Member] INVEGA SUSTENNA/XEPLION Represents information pertaining to INVEGA SUSTENNA/XEPLION, a product of the entity. AMPYRA or FAMPYRA [Member] AMPYRA/ FAMPYRA Represents information pertaining to AMPYRA/FAMPYRA, a product of the entity. BYDUREON [Member] BYDUREON Represents information pertaining to BYDUREON, a product of the entity. Represents royalty as a percentage of net sales under the collaborative agreements. Collaborative Arrangement, Royalty Rate Royalty rate (as a percent) Collaborative Arrangement, Effective Notice Period Required to be Served for Termination of Agreement Notice period required to be given before termination of agreement Represents the notice period required to be served before the termination of the agreement. Entity Well-known Seasoned Issuer Period after the date of the first commercial sale of the product for license expiration Represents the period after the date of the first commercial sale of the product in a particular country that the agreement will expire. Collaborative Arrangement, Period after Date of First Commercial Sale of Product for Expiration of Agreement Entity Voluntary Filers Collaborative Arrangement, Period for Resolving Default or Breach after Receipt of Notice for Termination of Agreement Period for resolving default or breach after the receipt of notice for termination of agreement Represents the period for resolving default or breach after the receipt of notice for termination of agreement. Entity Current Reporting Status Collaborative Arrangement, Royalty Rate upon Termination of Related Agreement Royalty rate upon termination of manufacturing and supply agreement (as a percent) Represents royalty rate upon termination of related agreement. Entity Filer Category Percentage of total annual requirement of product that can be obtained from second source manufacturer under the collaborative agreement. Collaborative Arrangement, Percentage of Total Annual Requirement of Product that Can be Obtained from Second Source Manufacturer Percentage of total annual requirement of product that can be obtained from second source manufacturer Entity Public Float Collaborative Arrangement, Royalty Rate for Specified Number of Units Royalty as a percentage of net sales from the first 40 million units Represents royalty as a percentage of net sales of specified number of units under the collaborative arrangement. Entity Registrant Name Royalty as a percentage of net sales beyond the first 40 million units Represents royalty as a percentage of net sales beyond specified number of units under the collaborative agreement. Collaborative Arrangement, Royalty Rate Beyond Specified Number of Units Entity Central Index Key Represents the threshold for the number of units sold which is used to determine the royalty rate under the collaborative agreement. Collaborative Arrangement, Number of Units Sold Threshold for Determination of Royalty Rate Threshold for number of units sold used to determine royalty rate The accumulated impairment losses as of the balance sheet related to intangible assets, excluding goodwill, having a projected indefinite period of benefit. Indefinite-Lived Intangible Assets, Excluding Goodwill, Accumulated Impairment Loss Accumulated Amortization Intangible Assets, Net Excluding Goodwill Accumulated Amortization and Impairment Loss Accumulated Amortization The accumulated amortization and impairment losses related to intangible assets, excluding goodwill as of the balance sheet date. Geographic Information Disclosure of the entity's accounting policy for geographic information. Geographic Information [Policy Text Block] Entity Common Stock, Shares Outstanding Schedule of Net Income (Loss) before Provision for Taxes by Geographical Area [Table Text Block] Schedule of income (loss) before provision for income taxes by geographical area Tabular disclosure of net income or loss before provision for income taxes by geographical area of the entity. Amount of operating loss and tax credit carryforwards subject to annual limitation. Represents the annual limitation of operating loss and tax credit carryforwards, before tax effects, that may be utilized to reduce future taxable income under enacted tax laws. Operating Loss and Tax Credit Carryforwards Annual Limitation Period after loss carryforwards utilized that tax returns remain open to examination Period after Loss, Carryforwards Utilized that Tax Returns Remain Open to Examination Represents the period after loss carryforwards have been utilized that tax returns remain open to examination. Number of Products Number of products Represents the number of products. Internal Revenue Service IRS Member and State and Local Jurisdiction [Member] Federal, State, and Local Represents the designated tax departments of the United States of America and state and local government entitled to levy and collect income taxes from the entity. Ireland IRELAND Alkermes Europe Ltd [Member] Alkermes Europe Ltd Represents information pertaining to Alkermes Europe, Ltd. Deferred Tax Liability, Related to Acquired Intellectual Property Represents the deferred tax liability related to acquired intellectual property. Net deferred tax liability related to acquired intellectual property Earnings Per Share Numerator [Abstract] Numerator: Description of the period of time, from the grant date, after which the equity-based award expires. Share-based Compensation Arrangement by Share-based Payment Award Expiration Term Expiration period Percentage of repricing premium on credit agreement being repaid if the prepayment is made in connection with a refinancing transaction Percentage of Repricing Premium on Credit Agreement if Prepayment is Made in Connection with Refinancing Transaction Represents the percentage of repricing premium on credit agreement being repaid if the prepayment is made in connection with a refinancing transaction. Percentage of Repricing Premium of Outstanding Credit Agreement if Prepayment is Made in Connection with Amendment to Agreement Resulting in Refinancing Transaction Percentage of repricing premium on outstanding credit agreement balance, if prepayment is made in connection with an amendment to the agreement resulting in a refinancing transaction Represents the percentage of repricing premium on the outstanding credit agreement balance if the prepayment is made in connection with an amendment to the agreement resulting in a refinancing transaction. Debt Instrument, Percentage of Present Value of Future Cash Flows Remaining under Existing Senior Credit Facilities Percentage of present value of future cash flows remaining under Existing Senior Credit Facilities Represents percentage of present value of the future cash flows remaining under the Existing Senior Credit Facilities. Term Loan B 1 [Member] Term Loan B-1 Represents the information pertaining to term loan B-1 under the new term loan facility. Term Loan B-1, due September 25, 2019 Term Loan B 2 [Member] Term Loan B-2 Represents the information pertaining to term loan B-2 under the new term loan facility. Term Loan B-2, due September 25, 2016 Debt Instrument, Original Issue Discount Original issue discount Represents the charge against earnings during the period for the amount of debt discount recognized at the issuance of the instrument in a debt modification. Debt Instrument, Pre-Payment Penalty Prepayment penalty Represents pre-payment penalty related to debt refinancing. Debt Restructuring [Line Items] Results of refinancing and repricing Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Document Fiscal Year Focus Modified Debt [Abstract] Modified debt: Document Fiscal Period Focus Schedule of debt refinancing interest expense recognized in condensed consolidated statement of operations and comprehensive income (loss) Tabular disclosure of debt refinancing related information. Schedule of Debt Refinancing Interest (Expense) [Table Text Block] Write off of Unamortized Discount Unamortized original issue discount Write-off of unamortized amount of debt discount that was originally recognized at the issuance in an extinguishment of debt. Product return reserve as percentage of product sales Represents the sales return reserve as percentage of sales revenue goods net at the end of the period. Sales Returns Reserve for Sales Returns as Percentage of Sales Revenue Goods Net Accumulated Derivative Income (Loss) [Roll Forward] Accumulated derivative loss for the interest rate swap Number of Other Existing Investors Number of other existing investors Represents the number of other investors, who agreed to provide a promissory note in the specified amount. Defined Contribution Plan Maximum Percentage of Participant Compensation Eligible for Employer Matching Contribution Percentage of employee pay matched by the employer Represents the maximum percentage of participants' eligible compensation for employer matching contribution. Interest rate, variable interest rate floor The floor for the variable rate base of the debt instrument. Debt Instrument, Variable Rate Basis Floor Interest rate, variable interest rate floor (as a percent) Debt Instrument Term before Amendment Term of loan before amendment Represents the term of the debt instrument before amendment. Accounting guidance related to the milestone method of revenue recognition adopted Income Tax Benefit Recorded Relating to Utilization of Certain Net Operating Loss Carryforwards Benefit recorded to additional paid-in capital Represents the income tax benefit recorded related to utilization of certain net operating loss carryforwards resulting from the exercise of employee stock options. Collaborative Arrangement Milestone Payments Entitled to be Received Upon Initiation of Phase Three Clinical Trial Milestone payment entitled to be received upon the initiation of phase 3 clinical trial Represents the amount of milestone payment entitled to be received upon the initiation of phase 3 clinical trial, under the collaborative arrangement. Collaborative Arrangement Milestone Payments Entitled to be Received Upon Acceptance of New Drug Application by Food and Drug Administration Milestone payment entitled to be received upon the acceptance of NDA by the FDA Represents the amount of milestone payment entitled to be received upon the acceptance of NDA by the FDA, under the collaborative arrangement. Legal Entity [Axis] Collaborative Arrangement Milestone Payments Entitled to be Received Upon Approval of New Drug Application by Food and Drug Administration Milestone payment entitled to be received upon the approval of NDA by the FDA Represents the amount of milestone payment entitled to be received upon the approval of NDA by the FDA, under the collaborative arrangement. Document Type ASC 718 Accounting Standards Update 2010-13 [Member] Collaborative Arrangement Milestone Payments Entitled to be Received Upon First Commercial Sale Milestone payment entitled to be received upon the first commercial sale Represents the amount of milestone payment entitled to be received upon the first commercial sale, under the collaborative arrangement. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nonrecourse Secured Notes Principal RISPERDAL CONSTA secured notes percentage. RISPERDAL CONSTA secured notes principal Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes attributable to original issue discount Payment of non-recourse 7% notes principal attributable to original issue discount. Payment of Non Recourse Product Secured Seven Percent Notes Principal Attributable to Original Issue Discount The amount of remaining performance obligations for the achievement of milestones. Revenue Recognition, Milestone Method Remaining Performance Obligations Remaining Performance obligations Represents the number of investments transferred into level 2 from level 1 of the fair value hierarchy. Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis, Number of Investments Transfer from Level 1 to Level 2 Number of investments transferred from level 1 to level 2 Collaborative Arrangement Additional Development Milestone Payment to be Earned Development milestone payment to be earned Represents the amount of additional development milestone payment to be earned by the entity under the collaborative agreement. Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Total accounts payable and accrued expenses Outplacement Services Costs Outplacement services Represents the amount of assistance that an employer provides to those employees affected by a layoff. Accelerated Depreciation Expense [Abstract] Expected accelerated depreciation Accelerated Depreciation Expense for Next Twelve Months 2014 Represents the expected amount of accelerated depreciation for the next twelve months following the latest fiscal year. Accelerated Depreciation Expense in Year Two 2015 Represents the expected amount of accelerated depreciation for the second fiscal year following the latest fiscal year. Income tax benefit due to utilization of NOL carryforwards Represents the amount of income tax benefit recognized due to utilization of operating loss carryforwards. Income Tax Expense Benefit Due to Utilization of Operating Loss Carryforwards Debt Restructuring [Table] Schedule detailing information related to debt restructurings. Debt Restructuring [Axis] Information related to debt restructurings. Debt Restructuring [Domain] Represents type of debt restructuring. Represents information pertaining to debt repricing by the reporting entity. Repricing of Debt [Member] February 2013 Repricing Represents the maximum amount of monthly financial assistance to qualified patients, assisting them with prescription drug co-payments that their insurance requires relative to their diagnosis. Maximum monthly co-pay assistance Maximum Monthly Co Pay Relief to Eligible Patients Net Impact of Timing Difference Error [Member] Represents the errors related to uncertain tax positions driven by timing differences that were not identified and disclosed in the prior years. Net impact of timing difference errors related to uncertain tax positions ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Employee Severance and Outplacement Services Costs [Member] Severance and outplacement services Represents the termination and outplacement services of employees associated with exit from or disposal of business activities or restructurings pursuant to a plan. Represents information pertaining to the other long-term liabilities. Other Long Term Liabilities [Member] Other long-term liabilities Accounts payable and accrued expenses Gross Unrealized Gains Available for Sale Securities Gross Unrealized Gain Accumulated in Investments Amount of accumulated unrealized gain before deducting unrealized loss on investments in available-for-sale securities impacting investments. Gross Unrealized Losses, Greater than One Year Available for Sale Securities Continuous Unrealized Loss Position 12 Months or Longer Aggregate Losses Accumulated in Investments Amount of accumulated unrealized loss on securities classified as available-for-sale securities that have been in a loss position for twelve months or longer impacting investments. Available for Sale Securities Continuous Unrealized Loss Position Less than 12 Months Aggregate Losses Accumulated in Investments Amount of accumulated unrealized loss on securities classified as available-for-sale securities that have been in a loss position for less than twelve months impacting investments. Gross Unrealized Losses, Less than One Year Amount of accumulated unrealized loss on investments in held-to-maturity securities that have been in a loss position for twelve months or longer. Held to Maturity Securities Continuous Unrealized Loss Position 12 Months or Longer Accumulated Loss Gross Unrealized Losses, Greater than One Year Held to Maturity Securities Continuous Unrealized Loss Position Less than 12 Months Accumulated Loss This item represents the excess of amortized cost basis over fair value of securities that have been in a loss position for less than 12 months for those securities which are categorized as held-to-maturity. Gross Unrealized Losses, Less than One Year Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences, assumed at the acquisition date. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Deferred Income Taxes Asset Liability Net Deferred tax liabilities Represents information pertaining to the paying off of an existing obligation from the proceeds of a new borrowing obtained by the entity. Debt Refinancing [Member] September 2012 Refinancing Rest of world Represents designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile, excluding the specified country. Foreign Country Excluding Specified Country [Member] Foreign Schedule of Earnings Per Share [Table] The table contains disclosure pertaining to the entity's dilutive securities. Earnings Per Share [Line Items] Computation of basic and diluted net income (loss) per share Held to Maturity Securities Accumulated Unrecognized Holding Gain Gross Unrealized Gains Amount of accumulated unrecognized gain on investments in held-to-maturity securities. Fair Value Measurement Conversion of Investment from Cost Method Investments to Available for Sale Securities Conversion of investment from cost method to available-for-sale Represents the amount of conversion of financial instrument from cost-method investments to available-for-sale securities. Property Plant and Equipment Estimated Useful Lives [Table Text Block] Tabular disclosure of the estimated useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Schedule of estimated useful life of property, plant and equipment TRANSITION PERIOD COMPARATIVE DATA Represents the entire disclosure pertaining to transition period comparative data during the reporting period. Transition Period Comparative Data Disclosure [Text block] TRANSITION PERIOD COMPARATIVE DATA Schedule of Transition Period Comparative Data Disclosure [Table Text block] Schedule of transition period comparative data Represents the tabular disclosure pertaining to transition period comparative data during the reporting period. Investment in Civitas Therapeutics, Inc. The cash outflow associated with the second acquisition of investments held by the entity for investment purposes not otherwise defined in the taxonomy. Payments to Acquire Investments Two Collaborative Arrangement Milestone Payments Received upon First Commercial Sale Milestone payment to be received upon the first commercial sale Represents the amount of milestone payments received upon the first commercial sale of exenatide products, including BYDUREON, under the collaborative arrangement. Income Tax Expense Benefit Related to Release of Valuation Allowance Recognized benefit related to release of valuation allowance Represents the amount of current income tax expense (benefit) and deferred income tax expense (benefit) relating to the release of a valuation allowance during the reporting period. Astra Zeneca[Member] AstraZeneca Represents information pertaining to AstraZeneca, a collaborative partner of the entity. Deferred Tax Liabilities Unrealized Gains on Securities Unrealized gains on investment Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on securities. Decreases due to lapse of statute of limitations and settlement of prior period uncertain tax positions Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations and settlement of prior period uncertain tax positions. Unrecognized Tax Benefits Reductions Resulting from Lapse of Applicable Statute of Limitations and Settlement of Prior Period Uncertain Tax Positions Income Tax Expense Benefit Related to Reversal of Valuation Allowance Recognized benefit related to reversal of valuation allowance Represents the amount of current income tax expense (benefit) and deferred income tax expense (benefit) relating to the reversal of a valuation allowance during the reporting period. Accounts Payable and Accrued Liabilities [Member] Accounts payable and accrued expenses Deferred Tax Assets Tax Deferred Expense Compensation and Benefits Exercise of Stock Options and Vesting of Restricted Stock Units Additional tax benefits from stock option exercises and the vesting of restricted stock units that have not been recognized The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from exercise of stock options and the vesting of restricted stock units, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. Deferred Tax Assets Tax Deferred Expense Compensation and Benefits Exercise of Stock Options and Vesting of Restricted Stock Units including Additional Tax Benefits Total tax benefit from the exercise of stock options and the vesting of restricted stock units including unrecognized benefits The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from exercise of stock options and the vesting of restricted stock units, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. This element includes the additional tax benefits from the exercise of stock options related to the adoption of ASC 718 that have not been recognized in the financial statements. Deferred Tax Assets Tax Credit Carryforwards State Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards. State tax credits Business Acquisition Number of Principal Drug Technology Platforms Number of principal drug technology platforms Represents the number of principal drug technology platforms acquired by the entity. Schedule of Assumptions used to Determine Fair Value of Warrants [Table Text Block] Schedule of assumptions used to determine the fair value of the warrants Tabular disclosure of the assumptions used to determine the fair value of the warrants. Amount of income tax expense (benefit) that has been provided on undistributed earnings of the Company's foreign subsidiaries. Provision for Income Tax on Undistributed Earnings of Foreign Subsidiaries Provision for income tax provided on undistributed earnings of foreign subsidiaries Net sales of below $250.0 million Net Sales Below 250 Million [Member] Represents the maximum net sales under the collaborative arrangement to determine the know how royalty percentage. Net Sales Between 250 and 500 Million [Member] Net sales between $250.0 million and 500.0 million Represents the range of net sales under the collaborative arrangement to determine the know-how royalty percentage. Net Sales Greater than 500 Million [Member] Net sales greater than $500.0 million Represents the minimum net sales under the collaborative arrangement to determine the know-how royalty percentage. Collaborative Arrangement Patent Royalty Rate Patent royalty rate (as a percent) Represents the patent royalty as a percentage of net sales under the collaborative agreements. Know-how royalty rate (as a percent) Collaborative Arrangement Know how Royalty Rate Represents the know-how patent royalty as a percentage of net sales under the collaborative agreements. Collaborative Arrangement Net Sales Tied to Know how Royalty Aggregate worldwide net sales Represents the aggregate worldwide net sales tied to know-how royalty under the collaborative agreements. Share Price of Equity Investment Current stock price (in dollars per share) Price of a single share of a number of saleable warrants of an equity investment. Stock Issued Issuance Costs Offering expenses Represents the equity offering costs related to the issuance of common during the reporting period. Accounts payable Accounts Payable, Current Accounts receivable Accounts Receivable [Member] U.S United States UNITED STATES Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Member] Cash flow hedge Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Estimated useful life of intangible assets acquired Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for Error Correction [Domain] Adjustments to reconcile net (loss) income to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Share-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Excess tax benefit from share-based compensation Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Total share-based compensation expense Allocated Share-based Compensation Expense Amortization of acquired intangible assets Amortization expense Amortization of Intangible Assets Reclassification from amortization of acquired intangibles Amortization of original issue discount and offering costs Amortization of offering costs and discount Amortization of Financing Costs and Discounts Antidilutive Securities [Axis] Denominator: Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Anti-dilutive potential common equivalent shares excluded from calculation of net (loss) income per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accretion expense Asset Retirement Obligation, Accretion Expense Asset Retirement Obligations Asset Retirement Obligation [Abstract] Asset retirement obligation Asset Retirement Obligations, Noncurrent Asset Retirement Obligations Asset Retirement Obligations, Policy [Policy Text Block] Impairment of long-lived assets Reclassification to impairment of long-lived assets Impairment of assets Asset Impairment Charges Balance at the beginning of the period Balance at the end of the period Asset Retirement Obligation Changes in the carrying amount of the company's asset retirement obligation Asset Retirement Obligation, Roll Forward Analysis [Roll Forward] TOTAL ASSETS Assets CURRENT ASSETS: Assets, Current [Abstract] ASSETS Assets [Abstract] Total current assets Current assets: Assets, Current Assets, Total Assets, Fair Value Disclosure Long-term assets: Assets, Noncurrent [Abstract] Net book value of assets Assets Held-for-sale, at Carrying Value Available-for-sale, Amortized Cost Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract] Within 1 year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Within 1 year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Available for sale securities Estimated Fair Value Available-for-sale Securities Total Available-for-sale Securities, Debt Maturities, Amortized Cost Basis Investments - short-term Available-for-sale Securities, Debt Securities, Current Available-for-sale, Estimated Fair Value Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Total Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value Amortized Cost Available-for-sale Securities, Amortized Cost Basis After 1 year through 5 years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Available-for-sale securities: Available-for-sale Securities [Abstract] After 1 year through 5 years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Balance Sheet Location [Axis] Balance Sheet Location [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Buildings and improvements Building and Building Improvements [Member] Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Business Acquisition [Axis] Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Schedule of unaudited pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Equity consideration in accordance with the merger agreement Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Value of ordinary shares issued as consideration in the acquisition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Acquisitions Business Acquisition [Line Items] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Revenues Business Acquisition, Pro Forma Revenue Business Acquisition, Acquiree [Domain] Net loss Business Acquisition, Pro Forma Net Income (Loss) ACQUISITIONS Total purchase price Business Combination, Consideration Transferred Ordinary shares issued as consideration in the acquisition Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory ACQUISITIONS Business Combination Disclosure [Text Block] Business Acquisitions Business Combinations Policy [Policy Text Block] Purchase price of the EDT business Business Combination, Consideration Transferred [Abstract] Property plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Acquired identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Expenses related to acquisition Business Combination, Acquisition Related Costs Unaudited pro forma information Business Combination, Pro Forma Information [Abstract] (Deprecated 2013-01-31) Purchase price allocation of assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Net loss from acquired business Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Revenues from acquired business Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Total Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash equivalents Cash Equivalents [Member] Cash-on-hand Cash and Cash Equivalents [Axis] Cash and cash equivalents CASH AND CASH EQUIVALENTS - Beginning of period CASH AND CASH EQUIVALENTS - End of period Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Designated as cash flow hedge Cash Flow Hedging [Member] Certificates of deposit Certificates of Deposit [Member] Class of Stock [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration Agreements Collaborative Arrangement [Member] COLLABORATIVE ARRANGEMENTS Collaborative Arrangement Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES (Note 16) Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Ordinary shares, par value (in dollars per share) Ordinary Shares Common Stock [Member] Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 145,137,639 and 138,482,571 shares issued; 144,444,951 and 137,792,626 shares outstanding at March 31, 2014 and December 31, 2013, respectively Common Stock, Value, Issued Common stock, shares issued Common Stock, Shares, Issued Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares outstanding Common Stock, Shares, Outstanding Components of the company's net deferred tax liabilities Components of Deferred Tax Assets and Liabilities [Abstract] COMPREHENSIVE (LOSS) INCOME: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE (LOSS) INCOME Concentration Risk Type [Domain] Concentrations Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk Type [Axis] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration risk percentage Concentration Risk, Percentage Principles of Consolidation Consolidation, Policy [Policy Text Block] Construction in progress Construction in Progress [Member] Research and development revenue Contracts Revenue Corporate debt securities Corporate securities Corporate Debt Securities [Member] Cost of goods manufactured and sold Cost of Goods Sold Investment in Acceleron Pharma, Inc., a collaborative partner Cost Method Investments Cost of goods manufactured and sold Cost of Sales [Member] EXPENSES: Costs and Expenses [Abstract] Total expenses Costs and Expenses Operating expenses Receivables Credit Concentration Risk [Member] Current income tax provision (benefit): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current income tax provision (benefit) Current Income Tax Expense (Benefit) Revenue Customer Concentration Risk [Member] Designated as hedging instrument Designated as Hedging Instrument [Member] Variable rate base Variable interest rate base Debt Instrument, Description of Variable Rate Basis Long-term debt Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Debt Conversion, Converted Instrument, Shares Issued Number of shares of Series B preferred stock issued on conversion of promissory note Fair value of remaining financial instruments not recognized at fair value Aggregate principal amount Debt Instrument, Face Amount Estimated Fair Value Debt Instrument, Fair Value Disclosure Interest rate, basis spread (as a percent) Interest rate added to base rate (as a percent) Debt Instrument, Basis Spread on Variable Rate LONG-TERM DEBT Debt Security [Axis] Conversion of promissory note into shares of Civitas Series B Preferred Stock Debt Conversion, Converted Instrument, Amount Amount of promissory note converted into Series B preferred stock Term loans maturity period Term of loan Debt Instrument, Term Offering costs Original issue discount Unamortized original issue discount Debt Instrument, Unamortized Discount Stated interest rate (as a percent) RISPERDAL CONSTA secured notes (as a percent) Stated interest rate on promissory note (as a percent) Debt Instrument, Interest Rate, Stated Percentage Required quarterly principal payments Scheduled principal payment Debt Instrument, Periodic Payment, Principal Debt financing costs Debt Related Commitment Fees and Debt Issuance Costs Property, plant and equipment Deferred Tax Assets, Property, Plant and Equipment Current deferred tax liabilities Deferred Tax Liabilities, Gross, Current Non-current deferred tax liabilities Deferred Tax Liabilities, Gross, Noncurrent Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Unamortized deferred financing costs at period end Deferred Finance Costs, Net Deferred income tax (benefit) provision: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred income taxes Deferred tax benefit Deferred income tax (benefit) provision Deferred Income Tax Expense (Benefit) Net deferred tax liabilities Deferred tax liability related to acquired intellectual property Deferred Tax Assets, Net Current deferred tax assets Deferred Tax Assets, Gross, Current Deferred revenue from milestone payment received prior to April 1, 2011 Deferred Revenue Deferred revenue - current Deferred revenue, short-term Deferred Revenue, Current Deferred revenue Deferred Tax Assets, Deferred Income DEFERRED REVENUE - LONG-TERM Deferred revenue, long-term Deferred Revenue, Noncurrent Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Bonus accrual Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses Other Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Federal research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred tax assets : Deferred Tax Assets, Net [Abstract] NOL carryforwards Deferred Tax Assets, Operating Loss Carryforwards Alternative minimum tax Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Less: valuation allowance Deferred Tax Assets, Valuation Allowance Other Deferred Tax Liabilities, Other DEFERRED TAX LIABILITIES, NET - LONG-TERM Deferred Tax Liabilities, Net, Noncurrent Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Intangible assets Deferred tax liability related to acquired intellectual property Deferred Tax Liabilities, Intangible Assets Total deferred tax liabilities Deferred Tax Liabilities, Net Deferred tax liabilities : Deferred Tax Liabilities, Gross [Abstract] Maximum percentage of employer contribution matched of employee's Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Percentage of employer contribution matched of the first employee pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Employer contribution Defined Contribution Plan, Cost Recognized Depreciation expense Depreciation Depreciation and amortization Depreciation, Depletion and Amortization Cost of interest rate cap Derivative, Cost of Hedge Interest rate swap contract Derivative Liability Derivative instruments Risk-management instruments Derivative [Line Items] Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instrument [Axis] Derivative [Table] Gain on derivative instrument due to change in fair value of the contract Derivative Instruments Not Designated as Hedging Instruments, Loss DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] DERIVATIVE INSTRUMENTS Interest rate cap contracts Derivative Asset Fair value of derivative instrument Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Fair value of derivative instrument Unrealized losses included in accumulated other comprehensive income, at the beginning of the period Unrealized losses included in accumulated other comprehensive income, at the end of the period Derivative Liability, Fair Value, Gross Liability Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of operations and comprehensive income (loss) Derivative, Gain (Loss) on Derivative, Net [Abstract] Unrealized losses included in accumulated other comprehensive income, at the end of the period Derivative, Loss on Derivative Derivative Contract [Domain] Risk-Management Instruments Derivatives, Policy [Policy Text Block] Directors Director [Member] SHARE-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION Irish Accrued compensation Due to Employees, Current EU European Union [Member] (LOSS) EARNINGS PER SHARE Earnings Per Share [Text Block] Earnings (Loss) Per Share Earnings Per Share, Policy [Policy Text Block] Basic (in dollars per share) Earnings Per Share, Basic Earnings per ordinary share - basic Diluted (in dollars per share) Earnings Per Share, Diluted Earnings per ordinary share - diluted (LOSS) EARNINGS PER ORDINARY SHARE: (LOSS) EARNINGS PER SHARE Estimated cost savings Effect on Future Earnings, Offset Amount Effective tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent R&D credit (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Reconciliation of the company's federal statutory tax rate to its effective rate Effective Income Tax Rate Reconciliation, Percent [Abstract] U.S. state income taxes, net of U.S. federal benefit (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Permanent items (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Change in valuation allowance (as a percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Statutory tax rate (as a percent) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State tax law change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Share-based compensation (as a percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Rate differential (as a percent) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Non-refundable withholding tax (as a percent) Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Share-based Compensation Expense Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock options Stock options Employee Stock Option [Member] Share based compensation cost capitalized Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted average period for unrecognized compensation cost expected to be recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition SHAREHOLDERS' EQUITY Increase in carrying value of equity method investment Equity Method Investment, Deferred Gain on Sale Carrying value of equity investment Equity Method Investments Ownership percentage Equity Method Investment, Ownership Percentage Investment, Name [Domain] Equity Component [Domain] Equity securities Equity Securities [Member] Adjustments for Error Corrections [Axis] Reclassifications Error Corrections and Prior Period Adjustments Restatement [Line Items] Total Estimate of Fair Value Measurement [Member] Excess tax benefit from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Excess tax benefit from share-based compensation Reclassification to excess tax benefit from share-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Extinguished debt: Extinguishment of Debt Disclosures [Abstract] Intangible assets acquired, finite-lived Finite-lived Intangible Assets Acquired Athlone, Ireland manufacturing facility Facility Closing [Member] Measurement Frequency [Axis] Volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Investments transferred into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Discount rate (as a percent) Fair Value Inputs, Discount Rate Investments transferred out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Measurement Frequency [Domain] Risk-free rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Expected term Fair Value Assumptions, Expected Term Transfer of securities from level 1 to level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Warrant strike price (in dollars per share) Fair Value Assumptions, Exercise Price Assumptions used to determine the fair value of the warrants Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Fair value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total unrealized losses included in other comprehensive (loss) income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) FAIR VALUE MEASUREMENTS Fair Value Hierarchy [Domain] Estimated fair value of term loans Fair Value Measurements, Nonrecurring [Table Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Roll forward of the fair value of the Company's investments whose fair value was determined using Level 3 inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Estimated fair value of the Term Loans Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, by Balance Sheet Grouping [Table] Schedule of rollforward of the fair value of the Company's investments whose fair value was determined using Level 3 inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Weighted Amortizable Life Finite-Lived Intangible Asset, Useful Life Gross Carrying Amount Finite-Lived Intangible Assets, Gross 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Three Expected amortization of intangible assets Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Expected amortization of intangible assets Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-lived intangible assets: Finite-Lived Intangible Assets, Net [Abstract] 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] International government agency debt securities Foreign Government Debt Securities [Member] Ireland Foreign Tax Authority [Member] Gain on foreign currency translation Foreign Currency Transaction Gain (Loss), before Tax Foreign Currency Foreign Currency Translation [Abstract] Loss on purchase of non-recourse RISPERDAL CONSTA secured 7% Notes Gain (Loss) on Non-Recourse Debt Loss on debt refinancing transaction Total Gains (Losses) on Extinguishment of Debt Goodwill and Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Impairment of goodwill Goodwill, Impairment Loss GOODWILL Goodwill Goodwill GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Gross Carrying Amount Goodwill, Gross GOODWILL AND INTANGIBLE ASSETS Hedging Designation [Axis] Hedging Designation [Domain] Held-to-maturity, Estimated Fair Value Held-to-maturity Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Within 1 year Held-to-maturity Securities, Debt Maturities, Next Twelve Months, Fair Value After 1 year through 5 years Held-to-maturity Securities, Debt Maturities, Year Two Through Five, Fair Value Held-to-maturity, Amortized Cost Held-to-maturity Securities, Debt Maturities, Net Carrying Amount [Abstract] Amortized Cost Held-to-maturity Securities, Amortized Cost before Other than Temporary Impairment Total Held-to-maturity Securities After 1 year through 5 years Held-to-maturity Securities, Debt Maturities, after One Through Five Years, Net Carrying Amount Held-to-maturity securities: Held-to-maturity Securities, Parenthetical Disclosure [Abstract] Gain (loss) on sale of held-to-maturity securities Held-to-maturity Securities, Sold Security, Realized Gain (Loss) Within 1 year Held-to-maturity Securities, Debt Maturities, within One Year, Net Carrying Amount Sale of held-to-maturity securities Held-to-maturity Securities, Sold Security, at Carrying Value Estimated Fair Value Held-to-maturity Securities, Fair Value Intangible assets acquired, indefinite-lived Indefinite-lived Intangible Assets Acquired Impairment charge Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Reduction in carrying value of investment of the entity, which represents the Company's share of investee's net losses Income (Loss) from Equity Method Investments CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME Statement of Operations Data: (LOSS) INCOME BEFORE INCOME TAXES Income (loss) before the provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income Statement Location [Axis] INCOME TAXES Income Tax Authority [Domain] Income Tax Authority [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Income Statement Location [Domain] Components of company's (benefit) provision for income taxes Income Tax Expense (Benefit), Continuing Operations [Abstract] Income tax (benefit) provision INCOME TAX PROVISION Income tax provision (benefit) Income Tax Expense (Benefit) Cash paid for taxes Income Taxes Paid Income Taxes Income Tax, Policy [Policy Text Block] Accounts payable and accrued expenses Reclassification from accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables Increase (Decrease) in Receivables Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Dilutive ordinary share equivalents (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Indefinite-lived Intangible Assets [Axis] Gross carrying amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived intangible assets: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Gross carrying amount Intangible Assets, Gross (Excluding Goodwill) INTANGIBLE ASSETS - NET Net Carrying Amount Intangible Assets, Net (Excluding Goodwill) Intangible assets Accrued interest Interest Payable, Current Interest expense Interest Expense Cash paid for interest Interest Paid Interest rate swap contract Interest rate swap Interest Rate Swap [Member] Interest rate caps Interest rate cap contracts Interest Rate Cap [Member] Federal U.S. Federal Internal Revenue Service (IRS) [Member] Inventory Total inventory Inventory, Net Finished goods Inventory, Finished Goods, Net of Reserves Raw materials Inventory, Raw Materials, Net of Reserves INVENTORY Inventory Disclosure [Text Block] Inventory Inventory, Policy [Policy Text Block] INVENTORY Work in process Inventory, Work in Process, Net of Reserves Interest income Investment Income, Interest Investments Investment, Policy [Policy Text Block] Investments [Domain] Investments Investment Holdings [Line Items] Investment Type [Axis] Investment Holdings [Table] The cost and fair value of available-for-sale and held-to-maturity securities by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Estimated Fair Value Investments, Fair Value Disclosure INVESTMENTS LIBOR London Interbank Offered Rate (LIBOR) [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Land Land [Member] Leasehold improvements Leasehold Improvements [Member] Total current liabilities Liabilities, Current TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity CURRENT LIABILITIES: Liabilities, Current [Abstract] Total liabilities Liabilities LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities, Total Financial and Nonfinancial Liabilities, Fair Value Disclosure Collaboration agreements Licensing Agreements [Member] Credit Agreement New Term Loan Facility Line of Credit [Member] 2013 2015 Total Carrying Value Long-term Debt. 2016 2014 LONG-TERM DEBT Long-term Debt [Text Block] Thereafter 2017 2015 Long-term Debt, Maturities, Repayments of Principal in Year Two 2017 Long-term Debt, Maturities, Repayments of Principal in Year Four 2018 Long-term Debt, Maturities, Repayments of Principal in Year Five Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five 2016 Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term debt - current Less: current portion Long-term Debt, Current Maturities LONG-TERM DEBT Long-term debt Long-term Debt, Excluding Current Maturities 2014 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Major Types of Debt Securities [Domain] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Customer [Axis] Total investments Marketable Securities [Abstract] Gross Unrealized Gains Marketable Securities, Unrealized Gain (Loss) INVESTMENTS - LONG-TERM Marketable Securities, Noncurrent INVESTMENTS Marketable Securities [Table Text Block] Scheduled maturities of Credit Agreement Maturities of Long-term Debt [Abstract] Maximum Maximum [Member] Minimum Minimum [Member] Money market funds Money Market Funds [Member] Long-term assets: Long-Lived Assets Customer [Domain] THE COMPANY Nature of Operations [Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] NET DECREASE IN CASH AND CASH EQUIVALENTS Net Cash Provided by (Used in) Continuing Operations NET (LOSS) INCOME Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Net (loss) income Cash flows (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash flows provided by operations Cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash flows provided by (used in) financing activities Cash flows used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash flows (used in) provided by investing activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Increase in product sales, net New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Revenue New accounting pronouncements New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Investment in Civitas Therapeutics, Inc. Noncash or Part Noncash Acquisition, Investments Acquired Purchased capital expenditures included in accounts payable and accrued expenses Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Total other (expense), net Nonoperating Income (Expense) Other expense (net) OTHER (EXPENSE), NET: Nonoperating Income (Expense) [Abstract] Non-voting Common Stock Nonvoting Common Stock [Member] Promissory note Financing Receivable, Gross Number of business segments Number of Reportable Segments Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Future minimum rental commitments under non-cancelable operating leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2017 Operating Leases, Future Minimum Payments, Due in Four Years 2018 Operating Leases, Future Minimum Payments, Due in Five Years Rent expense related to operating leases Operating Leases, Rent Expense, Net [Abstract] Sublease income Operating Leases, Rent Expense, Sublease Rentals 2016 Operating Leases, Future Minimum Payments, Due in Three Years Rent expense Operating Leases, Rent Expense, Net 2014 Operating Leases, Future Minimum Payments Due, Next Twelve Months OPERATING (LOSS) INCOME Operating Income (Loss) Less: estimated sublease income Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals 2015 Operating Leases, Future Minimum Payments, Due in Two Years Lease Commitments Operating Leased Assets [Line Items] Total future minimum lease payments before estimated sublease income Operating Leases, Future Minimum Payments Due Operating loss carryforwards Operating Loss Carryforwards THE COMPANY Unrealized (losses) gains on derivative contracts Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Unrealized gains on marketable securities, tax Other Comprehensive Income (Loss), Available-for-sale Securities, Tax Unrealized gains on marketable securities, net of tax of $8,217 and $372 for nine months ended December 2013 and and twelve months ended March 2012 respectively Unrealized (losses) gains on marketable securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Less: Reclassification adjustment for gains included in net income (loss) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Reclassification of unrealized gains to realized gains Less: Reclassification adjustment for losses included in net income (loss) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Reclassification of unrealized losses to realized losses OTHER ASSETS Other Assets, Noncurrent Other Unrealized gains (losses) on marketable securities Unrealized gains (losses) on marketable securities, net of tax: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax [Abstract] Holding (losses) gains, net of tax of $1,453 and none, respectively Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized losses on derivative contracts, net of tax of none, none and $(194), respectively Unrealized losses incurred during the period Unrealized loss on cash flow hedge, net of tax of $(194) for twelve months ended March 2012 Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Holding (losses) gains, tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized (losses) gains on derivative contracts: Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax [Abstract] Unrealized loss on cash flow hedge, tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax Unrealized losses on derivative contracts, tax Less: Reclassification adjustment for losses included in net (loss) income Unrealized losses Other Income Consigned-out inventory Other Inventory, Net of Reserves Other non-cash charges Other Noncash Expense Other (expense) income, net Other Nonoperating Income (Expense) OTHER LONG-TERM LIABILITIES Other Liabilities, Noncurrent Adjustments Other Restructuring Costs Accrued other Other Accrued Liabilities, Current Unrealized gains (losses) on marketable securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Products and Services [Domain] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Reclassification to employee taxes paid related to net share settlement of equity awards Employee taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Purchases of investments Payments to Acquire Marketable Securities Acquisition of Elan Drug Technologies, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Cash paid for restructuring costs Payments for Restructuring Cash paid for acquisition Upfront payment in accordance with the merger agreement Payments to Acquire Businesses, Gross Additions of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Promissory note issued to Civitas Therapeutics, Inc. Payments to Acquire Notes Receivable Investment in Acceleron Pharmaceuticals, Inc. Payments to Acquire Other Investments Additional investments Employee Benefit Plans Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] Plan Name [Domain] Plan Name [Axis] Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at March 31, 2014 and December 31, 2013, respectively Preferred Stock, Value, Issued Preferred shares, issued Preferred Stock, Shares Issued Preferred shares, authorized Preferred Stock, Shares Authorized Preferred shares, outstanding Preferred Stock, Shares Outstanding Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Reclassifications Reclassification, Policy [Policy Text Block] Proceeds from (Repayments of) Notes Payable Payment or purchase of non-recourse RISPERDAL CONSTA secured 7% notes Proceeds from the issuance of long-term debt Proceeds from Issuance of Long-term Debt Gross proceeds from issuance Proceeds from Issuance of Common Stock Proceeds from the issuance of ordinary shares, net Cash received from option exercises Proceeds from Stock Options Exercised Sales and maturities of investments Proceeds from the sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from the sale of equipment Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from the issuance of ordinary shares under share-based compensation arrangements Reclassification from proceeds from the issuance of ordinary shares under share-based compensation arrangements Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Products and Services [Axis] Estimated useful life Property, Plant and Equipment, Useful Life Subtotal Property, Plant and Equipment, Gross Carrying value at the time of disposition Property, Plant and Equipment, Disposals Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PROPERTY, PLANT AND EQUIPMENT, NET Total property, plant and equipment, net Property, Plant and Equipment, Net Net book value of assets PROPERTY, PLANT AND EQUIPMENT Schedule of property, plant and equipment Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Axis] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Property, plant and equipment Property, Plant and Equipment [Line Items] Reclassification of property plant and equipment Property, Plant and Equipment, Transfers and Changes Open purchase order commitments Purchase Commitment, Remaining Minimum Amount Committed Out-of-period adjustment recorded to correct an over-accrued liability from the prior year Quantifying Misstatement in Current Year Financial Statements, Amount Range [Axis] Range [Domain] Receivables Receivables, Net, Current Reclassification Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reconciliation of the beginning and ending amount of unrecognized tax benefits Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Principal payments of long-term debt Repayments of Long-term Debt Repayment of term loan Repayments of Debt IPR&D In-process research and development Research and Development Arrangement [Member] Research and development Research and Development Expense Research and development Research and Development Expense [Member] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Adjustments Restatement Adjustment [Member] Restricted stock units Restricted Stock [Member] Restructuring accrual Restructuring Reserve [Abstract] RESTRUCTURING Restructuring Charges [Abstract] Restructuring Total Payments Restructuring Charges Foreign currency adjustment Restructuring Reserve, Translation Adjustment Restructuring activity Restructuring and Related Cost [Line Items] Number of employees eliminated Restructuring and Related Cost, Number of Positions Eliminated Restructuring Type [Axis] Balance at end of the period Balance at beginning of the period Restructuring accrual Restructuring Reserve Accrued restructuring Expected number of employees to be eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated RESTRUCTURING Restructuring activity Restructuring Reserve [Roll Forward] RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING Accumulated Deficit Retained Earnings [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Revenue Recognition Revenue Recognition [Abstract] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Product return reserve Revenue Recognition, Sales Returns, Reserve for Sales Returns Revenue recognized Revenue by region: Revenues Geographic Information Revenues from External Customers and Long-Lived Assets [Line Items] Expected option term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Weighted average contractual remaining life Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term of stock options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Product sales, net Sales Revenue, Goods, Net Total revenues Revenue, Net Revenues REVENUES: Revenue, Net [Abstract] Scenario, Unspecified [Domain] Purchase price allocation of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of the Company's assets and liabilities measured at fair value on a recurring basis Schedule of Change in Asset Retirement Obligation [Table Text Block] Schedule of changes in the carrying amount of the company's asset retirement obligation Schedule of anti-dilutive potential ordinary equivalent shares excluded from calculation of net (loss) income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Summary of stock option activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Summary of time-vested RSU activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of fair value of each stock option grant estimated on the grant date using weighted-average assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of components of company's (benefit) provision for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of long-term debt Schedule of Debt [Table Text Block] Scheduled maturities with respect to the Term Loan Facility Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of goodwill and intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Schedule of reconciliation of the company's federal statutory tax rate to its effective tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of components of the company's net deferred tax liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of reconciliation of the beginning and ending amount of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of future minimum rental commitments under non-cancelable operating leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of revenues by geographic location, as determined by the location of the customer, and the location of its long-term assets Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of weighted average number of ordinary shares outstanding, as adjusted for the effect of potential outstanding shares, including stock options and restricted stock units Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of changes in accumulated derivative loss for the interest rate swap Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Operating Leased Assets [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Investment, Name [Axis] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Equity Method Investments [Table] Equity method investment Schedule of Equity Method Investments [Line Items] Schedule of share-based compensation expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Restructuring and Related Costs [Table] Property, Plant and Equipment [Table] Schedule of restructuring charges recorded Restructuring and Related Costs [Table Text Block] Summary of restructuring activity during the period Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of fair value and presentation in the condensed consolidated balance sheets for derivatives designated and not designated as hedging instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of revenue and receivables from customers exceeding 10% of total in each category Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Term Loans 2013 Term Loans Secured Debt [Member] Segment Information Segment Reporting [Abstract] Segment Information Segment Reporting, Policy [Policy Text Block] Geographical [Domain] Selling, General and Administrative Expenses [Member] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Severance Severance Costs Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Derived service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Unvested at the beginning of the period (in shares) Unvested at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected stock volatility, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected stock volatility, minimum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Share-based compensation expense Share-based Compensation. Risk-free interest rate, maximum (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Vesting period Minimum vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based compensation Share-Based Compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Unvested at the beginning of the period (in dollars per share) Unvested at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Share Price Share price (in dollar per share) Current stock price (in dollars per share) Purchase price (in dollar per share) Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum (as a percent) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Estimated dividend yield (as a percent) Expected annual dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Fair value of RSU's vested Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Shares of common stock authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Aggregate intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Shares of common stock authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Weighted-average assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average grant-date fair value of stock options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Stock options expected to vest Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Aggregate intrinsic value of stock options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Stock options expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Equity Award [Domain] Weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value BALANCE (in shares) BALANCE (in shares) Shares, Issued Short-term investments Short-term Investments [Member] Net reduction unrecognized tax benefits expected resolution of certain matters Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] U.S. state State and Local Jurisdiction [Member] State Scenario [Axis] Statement [Table] Statement Statement [Line Items] CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Geographical [Axis] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statement of Cash Flows Data: Equity Components [Axis] CONDENSED CONSOLIDATED BALANCE SHEETS Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Issuance of common stock to Elan Corporation, plc in connection with the purchase of Elan Drug Technologies (in shares) Stock Issued During Period, Shares, Acquisitions Value of shares authorized under repurchase program Stock Repurchase Program, Authorized Amount Issuance of common stock to Elan Corporation, plc in connection with the purchase of Elan Drug Technologies Stock Issued During Period, Value, Acquisitions Conversion of non-voting common stock to common stock Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock used in the acquisition of Elan Drug Technologies Stock Issued Issuance of common stock under employee stock plans (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Ordinary shares sold Stock Issued During Period, Shares, New Issues Number of ordinary shares sold Conversion of non-voting common stock to common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of common stock under employee stock plans Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Value of shares available for repurchase pursuant to repurchase program Stock Repurchase Program, Remaining Authorized Repurchase Amount SHAREHOLDERS' EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity, Period Increase (Decrease) Total shareholders' equity BALANCE BALANCE Stockholders' Equity Attributable to Parent SHAREHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Subsequent Event [Table] Subsequent events Subsequent Event [Line Items] Subsequent event Subsequent Event [Member] Subsequent Event Type [Domain] Subsequent Event Type [Axis] SUPPLEMENTAL CASH FLOW DISCLOSURE: Supplemental Cash Flow Information [Abstract] Title of Individual [Axis] Relationship to Entity [Domain] Trademark Trademarks [Member] Cancellation of treasury stock (in shares) Treasury Stock, Shares, Retired Treasury share Treasury Stock, Shares Cancellation of treasury stock Treasury Stock, Retired, Cost Method, Amount Treasury Stock Treasury Stock [Member] Treasury shares, at cost (692,688 and 689,945 shares at March 31, 2014 and December 31, 2013, respectively) Treasury Stock, Value Type of Arrangement and Non-arrangement Transactions [Axis] Type of Adoption [Domain] Type of Restructuring [Domain] Cumulative unremitted earnings of overseas subsidiaries Undistributed Earnings of Foreign Subsidiaries Additions based on tax positions related to the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Decreases due to settlements with tax authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Unrecognized tax benefit that would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Decreases due to lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Balance at the beginning of the period Balance at the end of the period Unrecognized Tax Benefits Discrete benefit from the settlement of uncertain tax benefits Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities Additions based on tax positions related to prior periods Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Use of Estimates Use of Estimates, Policy [Policy Text Block] U.S. government obligations US Government Debt Securities [Member] U.S. government and agency debt securities US Government Agencies Debt Securities [Member] Decrease in the valuation allowance due to the utilization of NOLs Valuation Allowance, Deferred Tax Asset, Change in Amount Variable Rate [Domain] Variable Rate [Axis] WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Basic (in shares) Weighted average number of ordinary shares outstanding Weighted Average Number of Shares Outstanding, Basic Weighted average ordinary shares outstanding - basic Diluted (in shares) Shares used in calculating diluted (loss) earnings per share Weighted Average Number of Shares Outstanding, Diluted Weighted average ordinary shares outstanding - diluted Unamortized deferred financing costs Write off of Deferred Debt Issuance Cost